Wire · opportunities
When a Failed Primary Endpoint Teaches More Than a Win: What CARDIOTTRansform's ...
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
The secondary analysis of the CARDIOTTRansform Phase 3 trial reveals that failure to adequately power and stratify for background transthyretin stabilizer therapy diluted the apparent efficacy of eplontersen, highlighting the need for trial designs to treat concomitant therapies as key treatment modifiers rather than background noise.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to redesign trials assuming patients arrive on standard therapies rather than treatment-naive. Trial power must cover key subgroups upfront or risk missing signals that matter for your drug's success.
◆ Coverage
1 source · 31 Aug 2026
◆ Related on Wire
◆ Topics